Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)

Xiuning Le; Eric Nadler; Daniel B. Costa; John Victor Heymach

doi:10.1007/s11523-023-01020-1

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)

Xiuning Le, Eric Nadler, Daniel B. Costa, John Victor Heymach

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

An Acknowledgment statement was added to this publication: Some of the research described in this review was funded in part through National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to DB Costa).

Original language	English (US)
Pages (from-to)	125
Number of pages	1
Journal	Targeted oncology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1007/s11523-023-01020-1
State	Published - Jan 2024

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s11523-023-01020-1

Fingerprint

Dive into the research topics of 'Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)'. Together they form a unique fingerprint.

Cite this

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2). / Le, Xiuning; Nadler, Eric; Costa, Daniel B. et al.
In: Targeted oncology, Vol. 19, No. 1, 01.2024, p. 125.

Research output: Contribution to journal › Comment/debate › peer-review

@article{5ba575a5ac5d4de7a09eccecdde95a89,

title = "Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)",

abstract = "An Acknowledgment statement was added to this publication: Some of the research described in this review was funded in part through National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to DB Costa).",

author = "Xiuning Le and Eric Nadler and Costa, {Daniel B.} and Heymach, {John Victor}",

note = "Publisher Copyright: {\textcopyright} 2023, Springer Nature Switzerland AG.",

year = "2024",

month = jan,

doi = "10.1007/s11523-023-01020-1",

language = "English (US)",

volume = "19",

pages = "125",

journal = "Targeted oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)

AU - Le, Xiuning

AU - Nadler, Eric

AU - Costa, Daniel B.

AU - Heymach, John Victor

PY - 2024/1

Y1 - 2024/1

N2 - An Acknowledgment statement was added to this publication: Some of the research described in this review was funded in part through National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to DB Costa).

AB - An Acknowledgment statement was added to this publication: Some of the research described in this review was funded in part through National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to DB Costa).

UR - http://www.scopus.com/inward/record.url?scp=85178925075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178925075&partnerID=8YFLogxK

U2 - 10.1007/s11523-023-01020-1

DO - 10.1007/s11523-023-01020-1

M3 - Comment/debate

C2 - 38070005

AN - SCOPUS:85178925075

SN - 1776-2596

VL - 19

SP - 125

JO - Targeted oncology

JF - Targeted oncology

IS - 1

ER -

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (Targeted Oncology, (2023), 18, 6, (807-817), 10.1007/s11523-023-00994-2)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this